Genprex preclinical data link low TROP2 levels to Reqorsa resistance in lung cancer
GNPX•Genprex said preclinical findings linked low TROP2 expression to resistance to its Reqorsa gene therapy in non-small cell lung cancer. Laboratory models showed that changing TROP2 levels increased treatment sensitivity, but further research and prospective clinical evaluation are needed.
1. Preclinical findings
Genprex presented findings at the EORTC-NCI-AACR Symposium in Barcelona, held November 18-20, 2026. Pretreatment tumor biopsies from clinical trial patients supported an association between low TROP2 expression and treatment resistance; modifying TROP2 levels also increased treatment sensitivity in laboratory models.
2. Further evaluation needed
The findings suggest TROP2 could potentially help guide patient selection for Reqorsa, but additional research and prospective clinical evaluation are needed to establish its role.




